Leerink Partners Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

Leerink Partners initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Thursday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $16.00 target price on the specialty pharmaceutical company’s stock.

Several other research firms also recently commented on TENX. StockNews.com began coverage on Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating on the stock. Guggenheim assumed coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, William Blair started coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Tenax Therapeutics Trading Down 0.6 %

Shares of NASDAQ:TENX opened at $4.75 on Thursday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20. The firm has a fifty day moving average of $3.79 and a 200 day moving average of $3.58.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.99) by $0.16. As a group, equities analysts anticipate that Tenax Therapeutics will post -6.75 earnings per share for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.